This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Petryk, M. Articles by Grossbard, M. L. Search for Related Content PubMed PubMed Citation Articles by Petryk, M. Articles by Grossbard, M. L.

Hematologic Malignancies

^a St. Luke's-Roosevelt Hospital Center; ^b Beth Israel Medical Center, New York, New York, USA

Correspondence: Michael L. Grossbard, M.D., St. Luke's-Roosevelt Hospital Center, 425 West 9th St., Suite 1A, New York, New York 10019, USA. Telephone: 212-523-5419; Fax: 212-523-2004; e-mail: mgrossbard{at}slrhc.org

This article reviews highlights in the field of hematologic malignancies presented at the 2001 annual meeting of the American Society of Clinical Oncology. Targeted therapies continue to proceed from the laboratory to the clinic. Monoclonal antibody-based therapies predominate, and further data on radioimmunoconjugates (RICs) (tositumomab and Iodine 131 tositumomab [Bexxar] and ibritumomab tiuxetan [Zevalin]) are presented. Both agents have high response rates in relapsed B-cell non-Hodgkin's lymphoma (NHL). Results from the first trial directly comparing an RIC (Zevalin) to an unconjugated antibody (rituximab) are presented. A novel application of RIC therapy as part of high-dose therapy for mantle cell NHL is described. A new fusion toxin, BL22, targets the CD22 antigen and shows marked activity in the treatment of hairy cell leukemia. Similarly, the Hu1D10 monoclonal antibody has activity in B-cell NHL and might have a relatively unique mechanism of action. Finally, advances in the treatment of mucositis are described. These abstracts all describe therapies derived from our enhanced understanding of tumor immunology and molecular biology.

Key Words. Monoclonal antibody • Radioimmunoconjugate • Rituximab • Tositumomab and 131I tositumomab • Ibritumomab tiuxetan